Pharmacological advances in the treatment of age-related macular degeneration.
Age related macular degeneration is an acquired degenerative disease that is responsible for severe loss of vision in elderly people. There are two types: Dry age related macular degeneration and wet age related macular degeneration. Its treatment has been improved and tries to be tailored in the future. The aim of this review is to summarize the pharmacological advances in the treatment of age-related macular degeneration. A PubMed search has been conducted looking for new molecules and treatments in age related macular degeneration. Regarding dry AMD there is no effective treatment to reduce its progression. However, some molecules such as lampalizumab and eculizumab were under investigation although have shown low efficacy. Herein that to try to prevent dry AMD progression the most important studies suggested increasing the antioxidants intake and quitting the smoke habit. On the hand, wet AMD have more developed treatment. Nowadays the gold standard treatment is anti-VEGF treatment. However more effective molecules are currently under investigation. There are different molecules in research for dry AMD and wet AMD. This fact could help us to treat our patients with more effective and lasting drugs but more clinical trials and safety studies are required in order to achieve an optimal treatment.